Budesonide/formoterol

Drug Profile

Budesonide/formoterol

Alternative Names: Alenia; Formoterol/budesonide; Symbicort; Symbicort pMDI; Symbicort SMART; Symbicort Turbuhaler

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biosintetica
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 27 Mar 2017 AstraZeneca completes a phase I bioavailability trial in Healthy volunteers in United Kingdom (Inhalation) (NCT02934607)
  • 31 Jan 2017 Launched for Asthma (In children) in USA (Inhalation)
  • 31 Jan 2017 Registered for Asthma (In children) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top